About this trial
Intra-abdominal candidiasis (IAC) is a frequent and severe fungal infection in critically ill patients, often diagnosed late. Its pathophysiology remains unclear, particularly regarding why some patients develop invasive infection while others only show benign colonization. A potential explanation lies in the state of innate immunity. Monocyte HLA-DR expression, a recognized marker of immune suppression in critical care, may be transiently but profoundly reduced in non-immunocompromised patients who go on to develop IAC. This observational study aims to evaluate whether patients with IAC have greater innate immune dysfunction-assessed by HLA-DR expression-compared to those with severe bacterial intra-abdominal infections. The goal is to better understand the immune mechanisms involved and improve early risk stratification for IAC.
Eligibility criteria
Qualifiers
Adult patient (≥ 18 years old)
Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery
Abdominal surgery within the last 7 days
Supramesocolic gastrointestinal perforation
Disqualifiers
Radiologically guided drainage without surgery
Infected acute pancreatitis
Limitation or withdrawal of life-sustaining treatments
Moribund patient with an expected life expectancy < 48 hours
Trial design
Treatments tested in this trial
- Immunomonitoring
Treatment groups
Sponsors and collaborators
Central Hospital, Nancy, France
Lead sponsor
Hospices Civils de Lyon
Collaborator